Abstract:Background: Cathelicidin LL-37 is the human member of a family of antimicrobial peptides that are released from activated neutrophils and monocytes at sites of acute inflammation.Recently it has been shown that LL-37 is a promising new biomarker for active antibodyassociated vasculitis both for prognosis and therapy guidance.We determined the association between circulating LL-37 levels and IBD disease activity, including strictures.Methods: Serum samples were collected from an institutional IBD biobank and separated into two cohorts.Cohort 1 was composed of 57 UC patients and 67 CD patients.Cohort 2 was composed of 21 UC patients and 28 CD patients.Cathelicidin serum levels were measured by ELISA.As our data indicated that LL-37 levels are inversely correlated to clinical IBD disease activity, the cohorts were divided into tertiles based on high, middle, and low cathelicidin levels.UC and CD clinical disease activity were quantified using Partial Mayo Score (PMS) and Harvey Bradshaw Index (HBI) respectively.Results: The age at blood sample collection, medication, CRP levels, and gender ratio of both cohorts are similar.In UC groups, cohort 1 has a longer duration of disease and higher PMS than cohort 2. In CD groups, cohort 2 has a lower HBI and more stricture patients than cohort 1.In UC patients, serum LL-37 levels in the low and middle tertiles (below 54 ng/mL) and CRP levels in the higher tertile (>2 mg/L) reflected moderate and severe clinical disease activity (PMS of 5 or above) with similar accuracy.The area under the curve (AUC) of the receiver operating characteristic (ROC) curves for both CRP and LL-37 were around 0.7, suggesting moderate accuracy.Alternatively, serum LL-37 levels in the high tertile (>54 ng/mL) and CRP levels in the lower tertile (<0.5mg/L) reflected UC remission (PMS of 0-2) with moderate accuracy (AUC=0.65).LL-37 was as accurate as CRP in indicating UC disease activity.In attempting to optimize the accuracy of LL-37 as an IBD biomarker, we found that co-existing low LL-37 levels and high CRP levels indicated moderate and severe UC with a high accuracy (AUC=0.80)better than that of either test alone.On the other hand, a combination of high LL-37 and low CRP levels indicated UC remission with higher accuracy (AUC=0.81)than either test alone (AUC= 0.64-0.66).High serum LL-37 levels (AUC=0.71)were also as accurate as low CRP levels (AUC=0.68) in indicating CD remission, although pairing the tests did not show an increase in accuracy.Low LL-37 levels and the remission status (HBI of 5 or less) of CD patients strongly indicated the presence of strictures with high specificity (0.90).Conclusion: The combination of circulating LL-37 with CRP levels and LL-37 levels with remission status can serve as a highly accurate biomarker for indicating clinical IBD disease activities and presence of stricture.

P066 Serum amyloid A – A Novel Biomarker of Ulcerative Colitis Disease Activity

Serum Amyloid A as a Potential Biomarker in Inflammatory Bowel Diseases, Especially in Patients with Low C-Reactive Protein

Clinical significance of serum anti-microbial antibodies test in inflammatory bowel disease

IDDF2019-ABS-0186 Correlation Between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

Serum amyloid protein A in inflammatory bowel disease: from bench to bedside

P138 Novel serum markers for predicting disease activity in ulcerative colitis: results from a retrospective case-control study

Assessment of IBD disease activity by Interleukin-6 and serum amyloid A in relation with fecal calprotectin and endoscopic indices

P452 Serum Amyloid A for Predicting Surgery and Disease Exacerbation in Patients with Newly Diagnosed Crohn’s Disease

ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?

Serum Amyloid A for Predicting Prognosis in Patients with Newly Diagnosed Crohn’s Disease

Serum amyloid A for predicting prognosis in patients with newly diagnosed Crohn's disease

P021 Higher TNFα and IL-6 mucosal levels in ulcerative colitis patients with more severe endoscopic activity

Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis

Current and emerging biomarkers for ulcerative colitis

P219 Prognostic potential of mucosal proteins in Ulcerative Colitis

Mo1318 Direct Comparison of In Vivo Drug Release Profiles of Three Locally-Acting Drug Products of Mesalamine in the Gastrointestinal Tract and Correlation With Systemic Exposure and Fecal Concentrations in Healthy Humans

The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient

Acute phase reactant serum amyloid A in inflammation and other diseases.

P336 Exploring Extracellular Matrix Markers in Ulcerative Colitis: Degradation and Formation Insights

Serum Glycan Markers for Evaluation of Disease Activity and Prediction of Clinical Course in Patients with Ulcerative Colitis

Circulating Extracellular Matrix Products as Indicators of Disease Burden and Predictors of Disease Course in Ulcerative Colitis